SG145716A1 - Amorphous rapamycin 42-ester with 3-hydroxy-2- (hydroxymethyl)-2- methylpropionic acid and pharmaceutical compositions containing the same - Google Patents

Amorphous rapamycin 42-ester with 3-hydroxy-2- (hydroxymethyl)-2- methylpropionic acid and pharmaceutical compositions containing the same

Info

Publication number
SG145716A1
SG145716A1 SG200805820-8A SG2008058208A SG145716A1 SG 145716 A1 SG145716 A1 SG 145716A1 SG 2008058208 A SG2008058208 A SG 2008058208A SG 145716 A1 SG145716 A1 SG 145716A1
Authority
SG
Singapore
Prior art keywords
hydroxymethyl
hydroxy
ester
pharmaceutical compositions
same
Prior art date
Application number
SG200805820-8A
Other languages
English (en)
Inventor
Eric J Benjamin
Muhammad Ashraf
Ashwinkumar Jain
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG145716(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SG145716A1 publication Critical patent/SG145716A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
SG200805820-8A 2003-09-03 2004-08-16 Amorphous rapamycin 42-ester with 3-hydroxy-2- (hydroxymethyl)-2- methylpropionic acid and pharmaceutical compositions containing the same SG145716A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49978903P 2003-09-03 2003-09-03

Publications (1)

Publication Number Publication Date
SG145716A1 true SG145716A1 (en) 2008-09-29

Family

ID=34272870

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200805820-8A SG145716A1 (en) 2003-09-03 2004-08-16 Amorphous rapamycin 42-ester with 3-hydroxy-2- (hydroxymethyl)-2- methylpropionic acid and pharmaceutical compositions containing the same

Country Status (25)

Country Link
US (2) US7271177B2 (de)
EP (1) EP1660081A1 (de)
JP (1) JP2007504226A (de)
KR (1) KR20060090803A (de)
CN (1) CN1874771A (de)
AR (1) AR045559A1 (de)
AU (1) AU2004270154A1 (de)
BR (1) BRPI0414066A (de)
CA (1) CA2536775A1 (de)
CO (1) CO5680426A2 (de)
CR (1) CR8293A (de)
EC (1) ECSP066473A (de)
GT (1) GT200400175A (de)
IL (1) IL173786A0 (de)
MX (1) MXPA06002123A (de)
NO (1) NO20061048L (de)
PA (1) PA8611201A1 (de)
PE (1) PE20050945A1 (de)
RU (1) RU2345999C2 (de)
SA (1) SA04250334B1 (de)
SG (1) SG145716A1 (de)
TW (1) TW200510428A (de)
UA (1) UA84881C2 (de)
WO (1) WO2005023254A1 (de)
ZA (1) ZA200601822B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1660081A1 (de) * 2003-09-03 2006-05-31 Wyeth Amorphe rapamycin 42-ester mit 3-hydroxy-2-(hydroxymethyl)-2-methylpropionsäure und diese enthaltende pharmazeutische zusammensetzungen
PT1701698E (pt) * 2004-01-08 2008-03-27 Wyeth Corp Composição farmacêutica para a administração oral de cci-779
US7349971B2 (en) * 2004-02-05 2008-03-25 Scenera Technologies, Llc System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information
CA2562952A1 (en) 2004-04-14 2005-11-10 Wyeth Regiospecific synthesis of rapamycin 42-ester derivatives
MXPA06012404A (es) * 2004-04-27 2007-01-17 Wyeth Corp Marcado de rapamicina usando metilasas especificas de rapamicina.
EP1781672B1 (de) * 2004-08-27 2010-10-06 Cordis Corporation Lösungsmittelfreies amorphes rapamycin
US20060094744A1 (en) * 2004-09-29 2006-05-04 Maryanoff Cynthia A Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
CA2595766A1 (en) 2005-02-09 2006-08-17 Wyeth Cci-779 polymorph and use thereof
JP2009518413A (ja) * 2005-12-07 2009-05-07 ワイス 精製結晶性ｃｃｉ−７７９を調製するためのプロセス
RU2008120670A (ru) * 2005-12-07 2010-01-20 Вайет (Us) Масштабируемый способ получения 42-сложного эфира рапамицина из 42-сложного эфира рапамицина бороната
CN101351702A (zh) * 2005-12-07 2009-01-21 惠氏公司 结晶雷帕霉素的制备方法以及使用差示扫描量热法测量雷帕霉素化合物结晶度的方法
CA2634056C (en) * 2005-12-21 2014-06-10 Eisai R&D Management Co., Ltd. Amorphous form of 1,2-dihydropyridine compound
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080234657A1 (en) * 2007-03-22 2008-09-25 Medtronic Vascular, Inc. Methods for contributing to cardiovascular treatments
JP2008305262A (ja) * 2007-06-08 2008-12-18 Konica Minolta Business Technologies Inc サーバ及びシンクライアント環境でのプリンタ紹介方法
US8852620B2 (en) 2007-07-20 2014-10-07 Medtronic Vascular, Inc. Medical devices comprising polymeric drug delivery systems with drug solubility gradients
US20090269480A1 (en) * 2008-04-24 2009-10-29 Medtronic Vascular, Inc. Supercritical Fluid Loading of Porous Medical Devices With Bioactive Agents
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
PT2365802T (pt) 2008-11-11 2017-11-14 Univ Texas Microcápsulas de rapamicina e utilização para o tratamento de cancro
US20100227799A1 (en) * 2009-03-09 2010-09-09 Medtronic Vascular, Inc. Simultaneous photodynamic therapy and photo induced polymerization
AU2010247766B2 (en) * 2009-05-12 2015-05-21 Corcept Therapeutics, Inc. Solid forms and process for preparing
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
CA2821524A1 (en) 2011-01-07 2012-07-12 Corcept Therapeutics, Inc. Combination steroid and glucocorticoid receptor antagonist therapy
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
DK2968281T3 (da) 2013-03-13 2020-11-02 Univ Texas Mtor-hæmmere til forebyggelse af vækst af tarmpolyp
MX371021B (es) * 2013-08-29 2020-01-13 Cadila Healthcare Ltd Procedimiento para preparar saroglitazar o sus sales farmaceuticamente aceptables.
JP6516743B2 (ja) 2013-11-25 2019-05-22 コーセプト セラピューティクス， インコーポレイテッド オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子
CA3206208A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CA3055076C (en) 2017-03-31 2022-02-22 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
EP3624863B1 (de) 2017-05-15 2021-04-14 C.R. Bard, Inc. Medizinische vorrichtung mit wirkstofffreisetzender beschichtung und zwischenschicht
WO2020101675A1 (en) 2018-11-14 2020-05-22 Lutonix, Inc. Medical device with drug-eluting coating on modified device surface
CA3121193C (en) 2018-12-19 2024-03-12 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
AU2020226863B2 (en) 2019-02-22 2023-04-06 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
WO2020209828A1 (en) 2019-04-08 2020-10-15 Bard Peripheral Vascular, Inc. Medical device with drug-eluting coating on modified device surface
EP4072556A4 (de) 2019-12-11 2024-01-03 Corcept Therapeutics Inc Verfahren zur behandlung von antipsychotikainduzierter gewichtszunahme mit miricorilant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
TWI256395B (en) * 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
DK1635830T3 (da) * 2002-09-17 2009-02-23 Wyeth Corp Granulatformulering af rapamycinesteren CCI-779
MXPA06000951A (es) * 2003-08-07 2006-03-30 Wyeth Corp Sintesis regioselectiva de cci-779.
EP1660081A1 (de) 2003-09-03 2006-05-31 Wyeth Amorphe rapamycin 42-ester mit 3-hydroxy-2-(hydroxymethyl)-2-methylpropionsäure und diese enthaltende pharmazeutische zusammensetzungen
PT1701698E (pt) 2004-01-08 2008-03-27 Wyeth Corp Composição farmacêutica para a administração oral de cci-779

Also Published As

Publication number Publication date
US20050049271A1 (en) 2005-03-03
MXPA06002123A (es) 2006-05-17
WO2005023254A1 (en) 2005-03-17
CR8293A (es) 2006-07-14
US7446111B2 (en) 2008-11-04
US7271177B2 (en) 2007-09-18
TW200510428A (en) 2005-03-16
EP1660081A1 (de) 2006-05-31
SA04250334B1 (ar) 2008-05-19
JP2007504226A (ja) 2007-03-01
RU2006110568A (ru) 2007-10-10
BRPI0414066A (pt) 2006-10-24
ZA200601822B (en) 2008-12-31
KR20060090803A (ko) 2006-08-16
PE20050945A1 (es) 2005-12-14
UA84881C2 (ru) 2008-12-10
IL173786A0 (en) 2006-07-05
RU2345999C2 (ru) 2009-02-10
CN1874771A (zh) 2006-12-06
CA2536775A1 (en) 2005-03-17
GT200400175A (es) 2005-04-18
AR045559A1 (es) 2005-11-02
CO5680426A2 (es) 2006-09-29
AU2004270154A1 (en) 2005-03-17
PA8611201A1 (es) 2005-05-10
ECSP066473A (es) 2006-10-10
NO20061048L (no) 2006-05-24
US20080070950A1 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
SG145716A1 (en) Amorphous rapamycin 42-ester with 3-hydroxy-2- (hydroxymethyl)-2- methylpropionic acid and pharmaceutical compositions containing the same
HK1084050A1 (en) Granulate formulation of the rapamycin ester cci-779
NO20050455L (no) Parenterale formuleringer inneholdende en rapamycinhydroksyester
HUP0400521A2 (hu) A CCI-779 alkalmazása daganatellenes szerként
WO2007028135A3 (en) Imidazopyridine compounds
AU2003259747A1 (en) Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
BRPI0518079A (pt) usos de um inibidor de mtor, de uma rapamicina, e de 42-éster de rapamicina com ácido 3-hidróxi-2- (hidroximetil) -2-metilpropiÈnico, composição farmacêutica, e, embalagem farmacêutica
EP1969939A3 (de) Nematizide Zusammensetzungen
MXPA06000407A (es) Isomero c cci-779.
WO2004063289A3 (en) Surface modification of carbonaceous materials with tri substituted aminoalkyl substituents
WO2007056175A3 (en) 41-methoxy isotope labeled rapamycin 42-ester
WO2004087073A3 (en) Treatment of demyelinating conditions
AU1044500A (en) Imidazonaphthyridines
WO2005054172A3 (en) Jasmonate derivative compounds, pharmaceuticals compositions and methods of use thereof
WO2002076396A3 (en) Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
TW200517116A (en) Method of treating mantle cell lymphoma
NO20082379L (no) Fremgangsmate for fremstilling av renset krystallinsk CCI-779
WO2003099783A3 (en) Tropane compounds
AU2003285261A1 (en) Compositions for the treatment of mycobacterial infections
AU2003249986A1 (en) Piece of equipment for an infantryman
AU2003274067A1 (en) Compounds for the treatment of cough
UA67578A (en) Antibacterial substance
RS20050620A (en) Nitrate esters of phenylaminothiophenacetic acid derivatives